Personalized CAR-T Immunotherapy Platform - … · GATACA CATCA TCA. Innovative Personalized CAR-T Immunotherapy Platform addresses unmet medical needs and drives development of precision

Personalized CAR-T Immunotherapy PlatformAccelerate your cancer research and drug discovery

www.diacarta.com www.promab.com

GLP, GMP, and CLIA-Certified Lab

Platform Overview

Powered by DiaCarta Genomics and ProMab CAR-T Technologies


1500 Existing Hybridomas andAntibody Engineering

5

4.5

4

3.5

3

2.5

2

1.5

1

0.5

0

Fluo

resc

ence

Cycle

Custom Lentiviral CAR Construction (GMP)

High-Throughput Multiplex Cytotoxicity Assays

In Vivo Efficacy and Toxicity Validation

CAR-T Cell Manu-facturing (GMP)

NRASEGFR VIII

CD19Biomarker Discovery

Genomic Profiling

Next-Generation Sequencing

CAR-T Infusion Treatment

QClamp®

Melting Profile

Comprehensive Services by the Personalized CAR-T Immunotherapy Platform

Genomic Profiling Biomarker discovery and CAR-T profiling

Gene mutation analysis by QClamp® XNA-PCR Gene expression by QuantiMarkerTM assaysOptiSeqTM next-generation sequencing GLP and CLIA lab settings

Cytokines Assays

Standard assays for cytokine detection in activated CAR-T cells (e.g. IL-2, IL-6, IFN-ϒ)Customized assays for quantitating up to 50 cytokines GLP and CLIA lab settings

CAR-T Services

Antibody discovery (hybridomas, mouse, rabbit and human library)Customized lentiviral CAR construction CAR-T cell manufacturing Real-time cytotoxicity assay (RTCA)Multiplex cytokine screeningMouse in vivo efficacy and toxicology modeling In vivo imaging by Xenogen/PerkinElmer IVIS systemGMP manufacturing of CD3/CD28 beads (coming soon) GMP manufacturing of lentiviral CAR (coming soon)

Bead-based multiplex protein tests run on Bio-Rad Bio-Plex® platform

Focus on generating CAR for murine-based pre-clinical studies or use as a clinical tool


In the era of the Cancer MoonShot 2020 Program - the nation’s most comprehensive cancer collabo-rative initiative to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients, DiaCarta and ProMab have joined hands to offer the next-genera-tion Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy platform.

About Our Platform

QClamp® XNA-PCR platform dramatically suppresses wild-type DNA template to provide ultra sensitive detection for mutant template. OptiSeqTM next-gen sequencing enriches mutant targets to enable 10x lower limit of detection than conventional methods. These platforms are ideal for the screening of human antibody libraries and detection of rare mutations in oncogenes such as NRAS and EGFR VIII as well as CD19-specifc chimeric antigen receptor. CytoPlexTM cytokine assays are solutions for assessing multiple protein biomarkers in a single tube, powered by a unique multiplex bar-coding technology. Using SuperbDNATM signal amplification technology, QuantiMarkerTM can effectively detect overexpression of tumor antigens and develop neo-tumor antigen discovery. CAR-T service is a completely inclusive program based on 1500+ antibody products from the generation of a single-chain variable fragment (scFV) targeting your tumor antigen to in vitro cytotoxicity analyses and in vivo animal modelling. The sophisticated computer modeling and bioinformatics approaches are applied to the antibody humanization projects. This repository and fully human antibodies provide a source of multi-affinity clones to tackle novel therapies and questions of cytotoxic specificity.


OptiSeqTM detects what other NGS platform missed

2 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39

5

4.5

4

3.5

3

2.5

2

1.5

1

0.5

0

Fluo

resc

ence

Cycle

Control

50% MT

10% MT

5% MT

1% MT

0.1% MT

QClamp® JAK2 V617F mutant dilution study shows < 0.1% detection sensitivity of mutant DNA

Real-Time Cytotoxicity Assay (RTCA) shows CD19 CAR NK cell’s cytotoxic activity and IFN-gamma

secretion by CD19 CAR T-cells

QClamp® detects mutant DNA template with ultra sensitivity (< 0.1%)

Features and Benefits at a Glance

QClamp® (qPCR)

Ultra sensitive: detect ≤ 0.1% mutationsRapid: turn around time ~ 2 hoursSample ready: suitable for liquid biopsy, FFPE sample and moreVersatile: works with most PCR machinesReproducible: robust XNA-PCR minimizes variability

OptiSeqTM (NGS)

Ultra sensitive: detect ≤ 0.1% mutations and < 1% indelsRapid: 10x lower sequencing depth in 3 to 5 days Accurate: fewer errors by enrich-ing mutant readsSample ready: suitable for ctDNA, CTC and FFPE samplesReproducible: robust XNA-PCR minimizes variabilityAffordable: reduce number of reads by 10x

CytoplexTM (Multiplex Protein Tests)

Mutiplex: measure 50 analytes simultaneously Rapid: turn around time 3 hours (analysis of up to 50 cytokines in 80 samples)Cost efficient: use only 25 to 50 µL of sample with lower amount of reagents Sensitive: bead-based assay with ultra signal amplification Streamlined: custom data interpre-tation and reporting

QuantiMarkerTM (Gene Expression Assays)Convenient: direct assay on samples without RNA purification Sensitive: signal amplification by SuperbDNATM technologyAccurate: quantitate original RNA population directly from lysatesSample ready: compatible with all tissues and fluid types Simple to use: standard ELISA- like assays with luminometer

CLIA-Certified Lab

Clinical operations in both United States and China with same LIMS and quality systemGMP-compliance lab over 18,000 square feetOncology and pathology expertiseHigh regulatory and compliance standardsFlexibility to handle evolving needsStrong customer support

CAR-T Services

Expertise in humanizing mouse-specific single chain variable fragment (scFv) to generateCAR-T cells with fully human extracellular recognition domain Capable of combined testing of CAR-T cells and checkpoint inhibitors plus modulators Productive and experienced in antibody development with 1500 commercial monoclonal antibodiesDedicated CAR-T scientists and project managers Total solution for precision medi-cine


ACGAGATACACATCA

TCA

Innovative Personalized CAR-T Immunotherapy Platform addresses unmet medical needs and drives development of precision medicines in cancer treatment.

DiaCarta, [email protected]

Discover more at www.diacarta.com and www.promab.com

ProMab, Inc. [email protected]


Documents

Personalized CAR-T Immunotherapy Platform - … · GATACA CATCA TCA. Innovative Personalized CAR-T Immunotherapy Platform addresses unmet medical needs and drives development of precision